Last reviewed · How we verify

AVELUMAB

FDA-approved approved Monoclonal antibody Quality 50/100

Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors.

Avelumab is a marketed immunotherapy that targets PD-L1, currently approved for metastatic Merkel Cell Carcinoma. Its key strength lies in its mechanism of action, which effectively restores immune responses against tumors by blocking the interaction between PD-L1 and PD-1/B7.1 receptors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameAVELUMAB
Drug classProgrammed Death Ligand-1 Blocker [EPC]
TargetPD-L1
ModalityMonoclonal antibody
PhaseFDA-approved
First approval2017

Mechanism of action

Avelumab works by targeting PD-L1, a protein that can inhibit the immune system's ability to fight cancer. By blocking PD-L1, Avelumab helps restore the immune system's function, allowing it to more effectively attack tumor cells. Additionally, Avelumab can trigger the destruction of tumor cells through a process called antibody-dependent cell-mediated cytotoxicity (ADCC).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: